Time filter

Source Type

Changzheng, China

Kim K.,Sungkyunkwan University | Lee J.H.,Gachon University | Kim J.S.,Yonsei University | Min C.K.,Catholic University of Korea | And 17 more authors.
American Journal of Hematology | Year: 2014

The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However, the differences in clinical characteristics between ethnic groups are not well-defined. In Asian countries, although the incidence of MM has been lower than that of Western countries, there is growing evidence that MM is increasing rapidly. The Asian Myeloma Network decided to initiate the first multinational project to describe the clinical characteristics of MM and the clinical practices in Asia. Data were retrospectively collected from 23 centers in 7 countries and regions. The clinical characteristics at diagnosis, survival rates and initial treatment of 3,405 symptomatic MM patients were described. Median age was 62 years (range, 19-106), with 55.6% of being male. Median overall survival (OS) was 47 months (95% CI 44.0-50.0). Stem cell transplantation was performed in 666 patients who showed better survival rates (79 vs. 41 months, P<0.001). The first-line treatments of 2,970 patients were analyzed. The overall response rate was 71% including very good partial response or better in 31% of the 2,660 patients those were able to be evaluated. New drugs including bortezomib, thalidomide, and lenalidomide were used in 36% of 2,970 patients and affected OS when used as a first-line treatment. Am. J. Hematol. 89:751-756, 2014. © 2014 Wiley Periodicals, Inc. Source

Li R.,Myeloma and Lymphoma Center | Qian J.,University of Houston | Qian J.,Cleveland Clinic | Zhang W.,Myeloma and Lymphoma Center | And 9 more authors.
British Journal of Haematology | Year: 2014

Tumour cell-derived heat shock proteins (HSPs) are used as vaccines for immunotherapy of cancer patients. However, it is proposed that the peptide chaperoned on HSPs, not HSPs themselves, elicited a potent immune response. Given that HSPs are highly expressed by most myeloma cells and vital to myeloma cell survival, we reasoned that HSPs themselves might be an ideal myeloma antigen. In the present study, we explored the feasibility of targeting HSPs themselves for treating multiple myeloma. We identified and chose HLA-A*0201-binding peptides from human HSPB1 (HSP27) and HSP90AA1 (HSP90), and confirmed their immunogenicity in HLA-A*0201 transgenic mice. Dendritic cells pulsed with HSPB1 and HSP90AA1 peptides were used to stimulate peripheral blood mononuclear cells from healthy volunteers and myeloma patients to generate HSP peptide-specific cytotoxic T lymphocytes (CTLs). HSP peptide-specific CTLs efficiently lysed HLA-A*0201+ myeloma cells (established cell lines and primary plasma cells) but not HLA-A*0201- myeloma cells in vitro, indicating that myeloma cells naturally express HSP peptides in the context of major histocompatibility complex class I molecules. More importantly, HSP peptide-specific CTLs effectively reduced tumour burden in the xenograft mouse model of myeloma. Our study clearly demonstrated that HSPs might be novel tumour antigens for immunotherapy of myeloma. © 2014 John Wiley & Sons Ltd. Source

He H.,Myeloma and Lymphoma Center | Fu W.,Myeloma and Lymphoma Center | Jiang H.,Myeloma and Lymphoma Center | Du J.,Myeloma and Lymphoma Center | And 5 more authors.
Leukemia Research | Year: 2015

Objective: To analyze the frequency, clinical characteristics, and prognosis of IGH deletion in multiple myeloma (MM). Methods: A total of 310 consecutive patients with multiple myeloma were analyzed. Among them 251 patients were newly diagnosed and 59 patients were previously treated, fluorescence in situ hybridization (FISH) with IGH break apart probes were done for each case. Patterns of IGH deletion, response rate, overall survival, and progression free survival were analyzed. Results: Several patterns of IGH deletion were identified, including monoallelic deletion of whole locus of IGH, monoallelic deletion of 3' IGH, monoallelic deletion of 5' IGH, biallelic deletion of 3' IGH deletion, and complicated deletions with various types. The incidence rate of IGH deletion was 22.7% (57/251) in newly diagnosed patients and 27.2% (16/59) in previously treated patients, no significant difference was found between the two groups (p= 0.375). IGH deletion was associated with κ light chain M component (p<. 0.001), 13q deletion (p= 0.006), and absence of t(4; 14)(p= 0.033). In the cases with 13q deletion, the frequency of IGH deletion is 3.5% (1/28) in patients with t(4;14) and 40.5% (32/79) in patients without t(4;14), significant difference was found (p= 0.006). We further analyzed the response rates of patients with IGH deletion who received a uniform induction regimen of PAD composing of bortezomib, epirubicin, and dexamethasone. Overall response rate (ORR) in patients with IGH deletion was better than that in patients without IGH deletion (87.5 vs. 73.6%, p<. 0.001), while no significant difference was found in survival analysis, either OS or PFS (p= 0.158 and p= 0.177, respectively). Conclusion: IGH deletion is frequent in multiple myeloma, the incidence rate was higher in patients with 13q deletion and without t(4;14). Patients with IGH deletion had better ORR to PAD induction therapy, while it has no influence on the prognosis of multiple myeloma. © 2015 Elsevier Ltd. Source

Zhao Q.,Myeloma and Lymphoma Center | Fu W.,Myeloma and Lymphoma Center | Jiang H.,Myeloma and Lymphoma Center | Du J.,Myeloma and Lymphoma Center | And 5 more authors.
Human Pathology | Year: 2015

Summary Although abnormal activation of the nuclear factor κB (NF-κB) signaling pathway plays an important role in the pathogenesis of diffuse large B-cell lymphoma (DLBCL), only a few studies have dealt with the relation of NF-κB activation to clinical outcomes in this disease. We analyzed the clinical characteristics of 147 consecutive DLBCL patients, examined paraffin-embedded tissues from 120 of them to identify the activation of the NF-κB pathway by using immunohistochemical staining, and performed an overall survival (OS) analysis. Expression of P-p65 and p52 was found in 30.0% (n = 36) and 35.8% (n = 43) of the patients, respectively. Coexpression of these factors was found in 16.7% (n = 14) of the cases. Patients were divided into 4 groups according to P-p65 and/or p52 expression: P-p65+ only, p52+ only, both P-p65+ and p52+, and both P-p65- and p52-. The 3-year OS rates in the 4 groups were 51.3%, 68.3%, 34.6%, and 85.8%, respectively (P =.006). Univariate analysis showed that early stage (P =.032), low International Prognostic Index score (P =.001), less than 2 extranodal metastases (P =.014), complete remission with chemotherapy (P <.0001), germinal-center B-cell-like subtype (P =.049), Ki-67 < 75% (P =.017), and P-p65- (P =.002) or p52- (P =.031) were associated with longer 3-year OS. Multivariate analysis indicated that P-p65 expression was an independent prognostic factor for shorter OS (P =.032). In conclusion, NF-κB pathway activation markers P-p65 and p52 predict poor survival in DLBCL patients. Source

Discover hidden collaborations